New hope for PBC patients: Long-Term drug trial aims to prevent liver failure
NCT ID NCT07216235
First seen Oct 31, 2025 · Last updated Jun 12, 2026 · Updated 30 times
Summary
This study tests whether the drug saroglitazar magnesium can prevent serious liver problems in people with primary biliary cholangitis (PBC), a chronic liver disease. About 386 adults already on standard treatment will receive either the drug or a placebo for several years. The goal is to see if the drug delays or prevents liver failure, need for transplant, or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.